Document is current
Any future updates will be listed below
-
Authors
Kotliar, Dylan https://orcid.org/0000-0002-7968-645X
Curtis, Michelle
Agnew, Ryan
Weinand, Kathryn https://orcid.org/0000-0001-8491-7251
Nathan, Aparna
Baglaenko, Yuriy
Slowikowski, Kamil
Zhao, Yu https://orcid.org/0000-0003-2632-7530
Sabeti, Pardis C. https://orcid.org/0000-0002-9843-1890
Rao, Deepak A. https://orcid.org/0000-0001-9672-7746
Raychaudhuri, Soumya https://orcid.org/0000-0002-1901-8265
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P01AI148102)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (UC2AR081023, R01AR063759, T32AR007530)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U01HG012009, R56HG013083, T32HG002295)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 11 July 2025
First Online: 3 September 2025
Competing interests
: S.R. is a founder for Mestag, on advisory boards for Pfizer, Janssen and Sonoma, and a consultant for AbbVie, Biogen, Nimbus and Magnet. D.A.R. is a coinventor on a patent using TPH cells as a biomarker in autoimmune diseases. P.C.S. is a cofounder of, shareholder in, and consultant to Sherlock Biosciences, and Delve Bio, as well as a Board member of and shareholder in Danaher Corporation. The other authors declare no competing interests.
